Javascript must be enabled to continue!
Abstract 1623: CITED2 modulates metastatic ability through effects on IKK-alpha in breast cancer cells
View through CrossRef
Abstract
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain-2 (CITED2) is a member of the CITED family of non-DNA binding transcriptional co-activators. Previously, we identified CITED2 as a novel facilitator of bone metastasis in murine mammary cancer. Extending these initial studies to human breast cancer, CITED2 mRNA expression was significantly elevated in patient samples of metastatic breast cancer relative to primary tumors, with highest levels in bone metastasis. To explore the functional impact of CITED2 in breast cancer metastasis, we stably reduced CITED2 expression in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468 cells, which are metastatic in animal models. While CITED2 knockdown had no effect on cell proliferation, it significantly reduced tumor migration and invasion in vitro and metastasis following intra-cardiac administration in athymic nude mice in vivo. To explore the mechanism responsible for these effects, we examined the impact of CITED2 knockdown on gene expression in MDA-MB-231 cells by microarray analysis. As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced along with several downstream targets of the NF-κB pathway (OPN, MMP9, uPA, SPARC, IL11 and IL-1β). In line with the reduced expression of IKKα, both canonical and non-canonical NF-κB signaling was inhibited following CITED2 knockdown. By ChIP assay, CITED2 was recruited to the promoters of IKKα, as well as the NF-κB targets OPN, MMP9, and SPARC. Finally, restoration of IKKα expression in MDA-MB-231 and MDA-MB-468 cells following CITED2 knockdown rescued their invasive ability. Collectively, these results suggest that CITED2 exerts its pro-metastatic effects in breast cancer cells via regulating IKKα.
Citation Format: Swaathi Jayaraman, Michele Doucet, Wen M. Lau, Scott L. Kominsky. CITED2 modulates metastatic ability through effects on IKK-alpha in breast cancer cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1623.
American Association for Cancer Research (AACR)
Title: Abstract 1623: CITED2 modulates metastatic ability through effects on IKK-alpha in breast cancer cells
Description:
Abstract
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain-2 (CITED2) is a member of the CITED family of non-DNA binding transcriptional co-activators.
Previously, we identified CITED2 as a novel facilitator of bone metastasis in murine mammary cancer.
Extending these initial studies to human breast cancer, CITED2 mRNA expression was significantly elevated in patient samples of metastatic breast cancer relative to primary tumors, with highest levels in bone metastasis.
To explore the functional impact of CITED2 in breast cancer metastasis, we stably reduced CITED2 expression in the human breast cancer cell lines MDA-MB-231 and MDA-MB-468 cells, which are metastatic in animal models.
While CITED2 knockdown had no effect on cell proliferation, it significantly reduced tumor migration and invasion in vitro and metastasis following intra-cardiac administration in athymic nude mice in vivo.
To explore the mechanism responsible for these effects, we examined the impact of CITED2 knockdown on gene expression in MDA-MB-231 cells by microarray analysis.
As confirmed at the mRNA and protein levels in both MDA-MB-231 and MDA-MB-468 cells, expression of the NF-κB regulator IKKα was significantly reduced along with several downstream targets of the NF-κB pathway (OPN, MMP9, uPA, SPARC, IL11 and IL-1β).
In line with the reduced expression of IKKα, both canonical and non-canonical NF-κB signaling was inhibited following CITED2 knockdown.
By ChIP assay, CITED2 was recruited to the promoters of IKKα, as well as the NF-κB targets OPN, MMP9, and SPARC.
Finally, restoration of IKKα expression in MDA-MB-231 and MDA-MB-468 cells following CITED2 knockdown rescued their invasive ability.
Collectively, these results suggest that CITED2 exerts its pro-metastatic effects in breast cancer cells via regulating IKKα.
Citation Format: Swaathi Jayaraman, Michele Doucet, Wen M.
Lau, Scott L.
Kominsky.
CITED2 modulates metastatic ability through effects on IKK-alpha in breast cancer cells.
[abstract].
In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.
Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1623.
Related Results
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
<span style="font-size: 11pt; color: black; font-family: 'Times New Roman','serif'">ΠΗΛΙΝΑ ΙΓ&Delta...
miR-409-3p represses
Cited2
at the evolutionary emergence of the callosal and corticospinal projections
miR-409-3p represses
Cited2
at the evolutionary emergence of the callosal and corticospinal projections
Abstract
Callosal projection neurons are a broad population of interhemispheric projection neurons that extend an axon across the corpus callosum...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Un manoscritto equivocato del copista santo Theophilos († 1548)
Un manoscritto equivocato del copista santo Theophilos († 1548)
<p><font size="3"><span class="A1"><span style="font-family: 'Times New Roman','serif'">ΕΝΑ ΛΑΝ&...
YAP1 and downstream gene alterations in metastatic breast cancer.
YAP1 and downstream gene alterations in metastatic breast cancer.
e13121
Background:
Metastatic breast cancer remains a major clinical challenge, characterized by poor prognosis and limited therapeuti...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...

